Combining antibodies to prevent HIV from escaping treatment
Complementing broadly neutralizing antibodies and autologous responses to restrict virus escape and durably suppress HIV-1
This study is looking at how to make HIV treatments better by finding new ways to combine special antibodies that can fight the virus, helping people living with HIV have more effective options for managing their condition.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11036395 on NIH RePORTER |
What this research studies
This research investigates how to enhance the effectiveness of broadly neutralizing antibodies (bnAbs) against HIV by combining them in a way that limits the virus's ability to escape treatment. The approach involves studying the immune response and mapping how the virus changes in response to these antibodies. By analyzing samples from patients, the research aims to identify new combinations of antibodies that can work together to suppress the virus more effectively. This could lead to improved therapies for individuals living with HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are currently undergoing treatment and may benefit from enhanced antibody therapies.
Not a fit: Patients who are not living with HIV or those who are not currently receiving treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for HIV, potentially improving the quality of life and health outcomes for patients.
How similar studies have performed: Previous research has shown promise in using combination therapies for HIV treatment, indicating that this approach could be effective.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Bar, Katharine June — University of Pennsylvania
- Study coordinator: Bar, Katharine June
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.